Clene Inc. CLNN Archives - Page 7 of 10

FridayMar 15, 2024 11:33 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human blood plasma that form the protein corona of the gold nanocrystals of CNM-Au8(R), Clene’s investigational drug in development for the treatment of neurodegenerative diseases. “The protein corona of CNM-Au8 gold nanocrystals, tailored for brain delivery…

WednesdayMar 13, 2024 12:17 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we will continue to advance our regulatory discussions with the U.S. Food and Drug Administration (‘FDA’) that we anticipate will include new data on biomarkers, as well as additional clinical function and survival data in people…

ThursdayMar 07, 2024 1:08 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). An archived version of the presentation will be available following the webcast on the company website.…

ThursdayFeb 29, 2024 10:08 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented the results at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in Florida. The results were gathered from the VISIONARY-MS trial long-term open label extension (“LTE”) in participants with stable…

TuesdayFeb 27, 2024 3:30 pm

QualityStocksNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function,” a recent article reads. The article discusses CNM-Au8 development pathways, which…

ThursdayFeb 22, 2024 1:18 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today reported new, significant survival results in amyotrophic lateral sclerosis (“ALS”) patients. According to the announcement, the results are from two independent analyses of pooled data from two intermediate-size “Companionate Use” Expanded Access Programs (“EAPs”) supported by the company. The EAPs provided access to treatment with CNM-Au8(R) to 256 participants, all people living with ALS who were generally too advanced in their disease to qualify for clinical…

TuesdayFeb 20, 2024 3:57 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements in vision and cognition for participants treated for nearly three years from randomization, with these results robust and consistent, according to Professor Michael Barnett, Professor of Neurology, Brain and Mind Centre, University of Sydney, and…

TuesdayFeb 13, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited CNM-Au8(R) has demonstrated remarkable efficacy across various nervous system cell types, with its ability to target fundamental deficiencies associated with dying neurons Gold nanocrystals found in CNM-Au8 act as miniature mitochondria, providing neurons with much-needed ATP energy while simultaneously converting toxic reactive oxygen species into harmless compounds Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking…

TuesdayFeb 06, 2024 12:08 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”). Etherington and Darling discussed the trial, which involved gathering almost three years of research and information from participants with stable relapsing MS. Darling explained…

TuesdayFeb 06, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE One of the trial’s key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical…

Site Search

Company Search

Tag: Clene Inc. CLNN